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The involvement of the homologous to E6-AP carboxyl terminus (HECT)-type E3s in crucial signaling path-
ways implicated in tumorigenesis is presently an area of intense research and extensive scientific interest.
This review highlights recent discoveries on the ubiquitin-mediated degradation of crucial tumor suppressor
molecules catalyzed by the HECT-type E3s. By providing a portrait of their protein targets, we intend to link
the substrate specificity of HECT-type E3swith their contribution to tumorigenesis. Moreover, we discuss the
relevance of targeting the HECT E3s, through the development of small-molecule inhibitors, as an anticancer
therapeutic strategy.Introduction
Protein ubiquitylation is a highly ordered multistep enzymatic
process accomplished by the formation of an isopeptide bond
between the C-terminal Gly76 carboxyl group of ubiquitin and
the 3-amino group of an internal Lys residue of the substrate
(Hershko and Ciechanover, 1998; Ciechanover, 1994, 2005;
Hershko, 2005).
After initial ATP-dependent activation by an E1 ubiquitin-acti-
vating enzyme (E1), the C-terminal carboxyl group of ubiquitin
forms a high-energy thioester bond with an active Cys group of
the E1 enzyme. Activated ubiquitin is then transferred to a spe-
cific Cys residue of one of a family of E2 ubiquitin-conjugating
enzymes (E2s) via a similar thioester linkage. The E3 ubiquitin li-
gases (E3s) play a critical role in the ubiquitin conjugation cas-
cade by recruiting ubiquitin-loaded E2s, recognizing specific
substrates, and facilitating or directly catalyzing ubiquitin trans-
fer to either the Lys residues (in most cases) or the N terminus
of their molecular targets. E3s modify protein substrates by
either monoubiquitylation or sequential attachment of ubiquitin
molecules to form polyubiquitin chains. In contrast to this canon-
ical pathway, monoubiquitylation of ubiquitin-binding domain
(UBD)-containing proteins can occur independently of E3s,
through direct recruitment of ubiquitin-loaded E2 enzymes by
UBDs (Hoeller et al., 2007).
The fate of ubiquitylated proteins is determined by the nature
of ubiquitin attachment and the type of isopeptide linkage form-
ing the polyubiquitin chain. When ubiquitin tagging to intracellu-
lar substrates occurs through Lys48-linked polyubiquitin chains,
proteins are generally labeled for 26S proteasome-mediated
recognition and proteolysis. Monoubiquitylation (Mukhopad-
hyay and Riezman, 2007) and the formation of multiubiquitin
chains by isopeptide bonds other than Lys48, such as Lys6
(Nishikawa et al., 2004), Lys29/33 (Chastagner et al., 2006;10 Cancer Cell 14, July 2008 ª2008 Elsevier Inc.Al-Hakim et al., 2008), and Lys63 (Deng et al., 2000; Wang et al.,
2001; Geetha et al., 2005; Adhikary et al., 2005; Herman-Bachin-
sky et al., 2007), regulate protein degradation as well as a wide
array of cellular activities in a proteolysis-independent manner.
In addition, nonproteolytic Lys6 and Lys11 polyubiquitin linkages
have been identified in vivo, and their accumulation correlates
with the pathogenesis of neurodegenerative disorders (Cripps
et al., 2006; Bennett et al., 2007). With few exceptions, single
or multiple monoubiquitylation of cell surface receptors triggers
receptor internalization and trafficking to the endosomal-lyso-
somal degradation pathway (Levkowitz et al., 1999; Haglund
et al., 2003; Di Fiore et al., 2003).
Based on the sequence homology of their E2-binding do-
mains, E3s can be generally classified into three subfamilies:
the homologous to E6-AP carboxyl terminus (HECT) domain-
containing E3s, the really interesting new gene (RING) finger do-
main-containing E3s, and the U box E3s.
The relevance of the E3s in several biological processes is em-
phasized in vivo by the observation that their genetic alteration,
abnormal expression, or dysfunction is often accompanied by
the occurrence of pathological disorders, including cancer. Sev-
eral enzymes belonging to the RING-finger subfamily of E3s have
been classified as either tumor suppressors or oncoproteins. It is
only recently that various HECT E3s have emerged as crucial
regulators of cancer development and therapy. Indeed, in view
of their substrate specificity, the E3s represent potentially attrac-
tive targets for anticancer treatment. This review will mainly em-
phasize the oncogenic activity of a few members of the HECT
subfamily of E3s.
General Overview of the HECT-Type E3s
The key signature of this E3 subfamily is the HECT domain,
a large C-terminal module of approximately 350 amino acids
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(E6-AP). The HECT domain associates with the E2 and provides
the catalytic E3 activity (Huibregtse et al., 1995).
The HECT E3s are unique among the E3s in that they possess
intrinsic catalytic activity. Their reaction cycle consists of three
steps: binding to an E2, loading ubiquitin on themselves through
the formation of a ubiquitin-thioester intermediate with the cata-
lytic Cys located at the C terminus of the HECT domain, and
transfer of ubiquitin to the target protein. Thus, unlike the
RING-finger E3s, which, although able to promote the formation
of ubiquitin chains, lack a catalytic site, the HECT E3s directly
catalyze substrate ubiquitylation.
The HECT domain consists of a larger N-terminal lobe contain-
ing the E2-binding site and a smaller C-terminal lobe including
the active-site Cys residue. Structural studies have revealed
that these two lobes are connected by a flexible hinge region,
which is critical for juxtaposing the catalytic Cys residues of
the E2 and E3 (i.e., the HECT domain) during ubiquitin transfer.
A conformational change involving an alteration in the relative
orientation of the two lobes is thought to facilitate the transthio-
lation reaction (Verdecia et al., 2003; Huang et al., 1999; G.M.
and A. Tramontano, unpublished data).
The substrate specificity of the HECT-type E3s is dictated by
protein-protein interaction domains, which account for their
classification into three further subfamilies: HERC E3s contain-
ing RCC1-like domains (RLDs), C2-WW-HECT E3s possessing
tryptophan-tryptophan (WW) domains, and SI(ngle)-HECT E3s
lacking either RLDs or WW domains (Scheffner and Staub,
2007).
The C2-WW-HECT E3s likely represent the best characterized
subgroup of HECT ligases. They consists of monomeric proteins
with a common general modular architecture composed of an
N-terminal protein kinase C (PKC)-related C2 domain, two to four
WW protein-interacting domains, and a C-terminal HECT do-
main (Schwarz et al., 1998) (Figure 1).
The C2 domain binds Ca2+ and phospholipids and is involved
in targeting the HECT E3s to intracellular membranes (Dunn
et al., 2004). The C2-WW-HECT E3s are found in several subcel-
lular locations, including the plasma membrane, early and late
endosomal compartments, and lysosomes (Marchese et al.,
2003; Angers et al., 2004). Some family members can transiently
enter the nucleus to target nuclear substrates for protein ubiqui-
tylation (Hamilton et al., 2001; Neumann et al., 2003; Gwizdek
et al., 2005; Trotman et al., 2007). The WW domains mediate li-
gase-substrate associations through interactions with a variety
of proline-rich motifs and proline-containing phosphoserine/
phosphothreonine sequences of the protein substrate. WW do-
mains display preference for the PPXY (PY) consensus se-
quence, though atypical interactions with unrelated modular do-
mains in target (Qiu et al., 2000; Marchese et al., 2003; Wegierski
et al., 2006) or adaptor and regulatory proteins (Courbard et al.,
2002; Oberst et al., 2007) have also been reported.
In addition to the conformational change occurring within the
HECT domain, further mechanisms controlling the catalytic
properties of the C2-WW-HECT E3s are based on the establish-
ment of intramolecular interactions (Gallagher et al., 2006; Wies-
ner et al., 2007). As an example, the C2 domain and a region of
the HECT module in close proximity to the catalytic Cys of
Smurf2 as well as of other C2-WW-HECT E3s are engaged ininhibitory associations. By interfering with ubiquitin thioester
formation, these interactions negatively regulate the E3 ubiquity-
lating activity and ultimately prevent its degradation (Wiesner
et al., 2007).
The C2-WW-HECT group is conserved from yeast to mam-
mals, and its evolution is schematically summarized in the phylo-
genetic tree shown in Figure 1. There is a single Nedd4 homolog
in S. cerevisiae, while three orthologs exist in S. pombe and flies.
In mammals, the family has further diverged by generating nine
homologs (Figure 1).
The C2-WW-HECT E3s typically regulate endocytosis and
trafficking of plasma membrane proteins through monoubiquity-
lation and the stability of both transmembrane receptors and
intracellular substrates via polyubiquitylation. Their subcellular
distribution, catalytic activity, and substrate specificity are sub-
jected to many levels of regulation, including posttranslational
modifications and interaction with adaptor and accessory pro-
teins (Shearwin-Whyatt et al., 2006). Adaptor proteins generally
possess PY motifs, which mediate direct interaction with WW
domains of the C2-WW-HECT E3s and facilitate their recruitment
to specific substrates (Shearwin-Whyatt et al., 2004; Oliver et al.,
2006). Alternatively, adaptor molecules can bridge between
C2-WW-HECT E3s and protein targets, which lack canonical
binding motifs (Qiu et al., 2000; Kavsak et al., 2000; Marchese
et al., 2003; Wegierski et al., 2006).
The oncogenic potential of the HECT-type E3s is highlighted
by the identification of a number of tumor suppressor molecules
among their protein substrates, as well as by the discovery of ge-
netic aberrations and altered expression patterns of some of the
family members in human cancers. Due to the crucial role ex-
erted by the HECT E3 adaptors and protein modifiers, it is pos-
sible that dysregulation of their regulators would also influence
cellular transformation. The main features of potentially onco-
genic HECT E3s and their regulators are summarized in Table 1.
SI(ngle)-HECT E3s
The best studied SI(ngle)-HECT E3s are E6-AP, Huwe1 (HECT,
UBA, and WWE domain containing 1), and E3 isolated by differ-
ential display (EDD), all of which have been associated with
tumor development.
E6-AP
The founding member of the HECT E3 family is E6-AP (also
called UBE3A), a 100 kDa polypeptide that interacts with the
E6 protein of the cervical cancer-related human papillomavirus
(HPV) (reviewed in Narisawa-Saito and Kiyono, 2007). E6-AP
forms a stable complex with the adaptor protein E6. The dimeric
complex binds to and targets p53 for ubiquitin-mediated prote-
olysis, thus eventually interfering with the negative growth-regu-
lating activities of this tumor suppressor protein (Scheffner et al.,
1990; Huibregtse et al., 1991, 1993a; Scheffner et al., 1994)
(Figure 2).
Though E6-independent substrates have been identified (Ku-
mar et al., 1999), E6-AP does not recognize p53 in the absence
of the viral oncoprotein E6 (Talis et al., 1998). The recognition of
E6 and p53 requires an approximately 200 amino acid region of
E6-AP, located at the N-terminal end of the HECT domain (Hui-
bregtse et al., 1993b). The E6:E6-AP complex binds to the DNA-
binding domain of p53, which becomes rapidly ubiquitylated and
is targeted to proteasomes (Huibregtse et al., 1991).Cancer Cell 14, July 2008 ª2008 Elsevier Inc. 11
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ReviewFigure 1. Phylogenetic Relationship Tree of Different Members of the C2-WW-HECT Family of E3s
(A) Orthologs of Nedd4 have been identified in yeast (red), fly (blue), and mouse and human (black). Itch clusters with WWP1 and WWP2, while Nedd4-1 and 2, the
Smurfs, and NEDL1 and 2 form separate clusters.
(B) The C2-WW-HECT E3 modular structure consists of an N-terminal Ca2+/lipid-binding (C2) domain (yellow rectangles), a central region containing multiple
WW domains (red squares), and a ubiquitin-protein ligase HECT domain (teal rectangles). The HECT domain contains a conserved catalytic Cys residue involved
in the formation of a ubiquitin-thioester intermediate.The ability to promote p53 degradation is an exclusive prereq-
uisite of E6 from the high-risk HPV types (type 16 and 18). On the
contrary, the E6 proteins from low-risk HPV types do not stably
interact with E6-AP (Huibregtse et al., 1991). This provides a rea-
sonable explanation for the relatively weak interaction of low-risk
E6s with p53 and their inability to induce degradation of p53.
Consistently, the majority of cervical cancer associated with
the high-risk HPV types harbors a wild-type p53 gene, and the
protein levels of p53 are extremely low. E6:E6-AP-induced inac-
tivation of p53 plays a role in the development of more than 90%
of human cervical carcinomas.
Although several other targets of E6-AP have been suggested
as potential mediators of its tumorigenic activity (Liu et al.,
2005a), the major contribution of E6-AP to tumor development
is thought to be achieved through the inactivation of p53.
Huwe1
Huwe1 (also named ARF-BP1, E3Histone, HectH9, LASU1,
Mule, and Ureb1) is a large protein (500 kDa) whose function
remains controversial. The substrates reported for this E3 in-
clude Cdc6 (Hall et al., 2007), histones (Liu et al., 2005b), Mcl-1
(Zhong et al., 2005), c-Myc (Adhikary et al., 2005), and p53 (Chen
et al., 2005a). Probably the most puzzling aspect of the contro-
versy surrounding this E3 is apparent from two studies published
in the same issue of the journal Cell that reported entirely oppo-
site phenotypes (both observed in U2OS cells) following silenc-
ing of Huwe1 (Chen et al., 2005a; Zhong et al., 2005). The two
divergent effects (i.e., increased survival versus increased apo-
ptosis) were linked to the ubiquitin-mediated degradation of
either Mcl-1 (an antiapoptotic protein) or p53 (a proapoptotic
protein).
Although Huwe1 targets Mcl-1 for protein ubiquitylation, ac-
cess of the E3 to Mcl-1 is not evident until cells are exposed to
DNA-damaging agents (Zhong et al., 2005). As reported by12 Cancer Cell 14, July 2008 ª2008 Elsevier Inc.Chen and colleagues (2005a), under unstressed conditions,
Huwe1 directly binds to and ubiquitylates p53 (Figure 2). It was
suggested that the tumor suppressor ARF might bind to the
HECT domain of Huwe1 and inhibit its ligase activity, thus pre-
venting p53 protein ubiquitylation (Chen et al., 2005a). Experi-
ments conducted in a HDM2 null genetic background have con-
firmed that ARF-induced stabilization of p53 also involves
Huwe1. However, others have been unable to demonstrate the
inhibitory activity of ARF toward Huwe1 (Adhikary et al., 2005).
More recently, Huwe1 was shown to be incapable of control-
ling p53 abundance in response to DNA-damage stress, while
other substrates such as Mcl-1 and Cdc6 are ubiquitylated and
degraded (Hall et al., 2007). In addition, the steady-state protein
levels of p53 are not increased by depletion of Huwe1 in neuro-
blastoma cells (Zhao et al., 2008).
Despite this unresolved controversy in the field, it is interesting
to note that the Huwe1 gene is highly expressed in a significant
proportion of lung and breast carcinomas (Adhikary et al., 2005;
Chen et al., 2005a). Huwe1 overexpression has also been asso-
ciated with colorectal carcinomas, in which the expression of the
E3 directly and inversely correlates with tumor stage and p53
protein levels, respectively (Adhikary et al., 2005; Yoon et al.,
2005). The majority of colon cancer samples displaying reduced
or absent expression of p53 do not harbor p53 mutations.
Finally, it was also suggested that Huwe1 assembles Lys63-
linked polyubiquitin chains on c-Myc and that this modification
is required for gene activation by c-Myc, allowing the interaction
of c-Myc with the p300 coactivator (Adhikary et al., 2005). How-
ever, other data seem to contradict this hypothesis. First, post-
translational modifications of c-Myc do not appear to be required
for its interaction with p300, because this complex can be effi-
ciently reconstituted in vitro using bacterially expressed (and
therefore unmodified) proteins (Faiola et al., 2005; Vervoorts
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E3 Substrate(s)
Outcome of Substrate
Ubiquitylation Adaptors/Regulators Biological Function Alterations in Cancer
E6-AP p53 proteasomal degradation E6 apoptosis infection by high-risk HPV
in cervical carcinomas
Huwe1 p53 proteasomal degradation ARF apoptosis, growth arrest overexpression in breast,
lung, and colorectal
carcinomas
EDD TopBP1 proteasomal degradation unknown DNA damage amplification and
overexpression in breast
and ovarian cancers
Nedd4-1 PTEN, Hgs, Eps15 proteasomal degradation,
cytoplasmic/nuclear
shuffling
unknown apoptosis, genome
integrity, endocytosis
overexpression in bladder
and prostate carcinomas
Nedd4-2 Smad2, Smad4,
TbR-I/II
proteasomal degradation Smad6, Smad7 apoptosis, growth arrest unknown
Itch p73, p63, Notch1,
c-Jun
proteasomal degradation Numb apoptosis, differentiation unknown
WWP1 p53, Notch1,
KLF2, KLF5, Smad2,
Smad4, TbR-I/II
proteasomal degradation,
nuclear export
Smad2, Smad6,
Smad7
apoptosis, growth arrest amplification and
overexpression in prostate
and breast cancers
Smurf1 Smad1, Smad4,
Smad5, TbR-I/II,
BMP-RI/II
proteasomal/lysosomal
degradation
Smad6, Smad7 apoptosis, growth arrest amplification and
overexpression
in pancreatic cancers
Smurf2 Smad1, Smad2,
Smad4, Smad5,
TbR-I/II
proteasomal/lysosomal
degradation
Smad2, Smad7 apoptosis, growth arrest overexpression in
esophageal squamous cell
carcinomas
TopBP1, topoisomerase IIb binding protein; BMP-R, bone morphogenetic protein receptor.et al., 2003, 2006). Second, Huwe1 has recently been found to
ubiquitylate N-Myc through Lys48-mediated linkages and target
it for destruction by the proteasome (Zhao et al., 2008).
As Huwe1 has only recently become a target of research, it is
clear that more time is required to resolve the various published
discrepancies.
C2-WW-HECT E3s
Nedd4
Nedd4 is the product of the neural precursor cell-expressed de-
velopmentally downregulated gene 4-1 (Nedd4-1). Nedd4-1 and
its closely related homolog Nedd4-2 were originally implicated in
regulation of fluid and electrolyte homeostasis by controlling the
surface abundance of epithelial cell sodium channel subunits
(Staub et al., 1997; Harvey et al., 1999). Recently, however, the
identification of the tumor suppressor PTEN as a substrate for
Nedd4-1 has extended its role to cancer development. The
PTEN gene, encoding a plasma membrane lipid phosphatase
that antagonizes phosphatidylinositol 3-kinase (PI3K)/AKT sur-
vival signaling, is frequently mutated or deleted in human can-
cers. Nedd4-1-mediated ubiquitylation of PTEN delivers a dual
signal for PTEN fate. Polyubiquitylation by Nedd4-1 is thought
to target PTEN for proteasomal degradation (Wang et al.,
2007), while covalent attachment of a single ubiquitin molecule
favors its nuclear translocation (Trotman et al., 2007) (Figure 3).
An alternative inactivation pathway of PTEN during tumorigene-
sis occurs as a result of Nedd4-1 overexpression in human blad-
der and prostate carcinomas, in which aberrant degradation of
PTEN would promote AKT signaling and ultimately provide cellsurvival advantage (Wang et al., 2007). The oncogenic activity
of Nedd4-1 is further corroborated by its ability to cooperate
with K-Ras in inducing cellular transformation in a PTEN-depen-
dent fashion.
Similarly to the HDM2:p53 paradigm, Nedd4-1 can also pro-
mote PTEN nuclear import and cytoplasmic/nuclear shuffling by
targeting Lys289 and Lys13 for monoubiquitylation (Trotman
et al., 2007). Nuclear transport of PTEN would potentiate its newly
discovered nuclear function in controlling chromosomal integrity
and cell death (Trotman et al., 2007; Shen et al., 2007) (Figure 3).
The dual behavior of Nedd4-1 may be governed by several fac-
tors, including amount, subcellular localization, regulation by
posttranslational modifications, and availability of protein adap-
tors for the E3. The regulatory pathways governing Nedd4 activity
were elegantly reviewedby Shearwin-Whyatt et al. (2006). Of note,
the enzymatic activity of the HECT E3s can be modulated by their
interaction with adaptors. As an example, the ability of the S. cer-
evisiae ortholog of Nedd4, Rsp5 (Figure 1), to switch from mono-
to polyubiquitylation of its substrates is strictly dependent on
availability of the adaptors Bul1p and Bul2p (Helliwell et al.,
2001). No less relevant, modifications of PTEN would also deter-
mine its fate by modulating the levels of ubiquitin conjugation.
An additional controversy in the field has been brought to light
by a recent report showing that knockout of Nedd4-1 does not
influence degradation or subcellular localization of PTEN (Fou-
ladkou et al., 2008). It remains a challenge for future research
to further validate a role for Nedd4-1 as a master regulator of
PTEN and to identify the physiological signals that trigger PTEN
destruction versus nuclear translocation.Cancer Cell 14, July 2008 ª2008 Elsevier Inc. 13
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p53 inactivation plays a primary role in human tumorigenesis. Besides gene mutation or deletion, accelerated degradation (A and B) and cytoplasmic seques-
tration (C) of p53 may account for the loss of its tumor-suppressive transcriptional activity.
(A and B) Two SI(ngle)-HECT E3s have been implicated in aberrant ubiquitin-dependent p53 proteolysis in human cancers: E6-AP catalyzes p53 ubiquitylation by
acting in concert with the viral oncoprotein E6 as an auxiliary factor (A), and similarly to the ARF-HDM2/p53 axis, Huwe1-induced ubiquitin proteasomal degra-
dation of p53 is repressed by the tumor suppressor ARF (B). Huwe1 possesses a C-terminal HECT domain, which is responsible for its ubiquitin ligase activity.
(C) WWP1-mediated ubiquitylation of p53 is likely to generate multiubiquitin chains by isopeptide bonds other than Lys48. This modification targets p53 for nu-
clear export and increases its protein stability in the cytoplasmic compartment. Reduced levels of p53 in the nucleus would hence diminish the ability of p53 to
transactivate its target promoters.In addition, it has been proposed that Nedd4 may play a role in
regulating the initial sorting events that promote ligand-depen-
dent endocytosis of receptor tyrosine kinases (RTKs). Nedd4-
mediated ubiquitylation of endocytic adaptors, involved in cou-
pling ubiquitylated membrane cargo to the endocytic machinery,
would promote the disassembly or inactivation of multiprotein
endocytic complexes and thus negatively regulate receptor en-
docytosis (Polo et al., 2002; Katz et al., 2002). These findings
provide grounds for speculating that overexpression of Nedd4-1
may contribute to tumorigenesis by inhibiting endocytosis of
activated RTKs, thereby enhancing receptor activation.
WWP1
A potential oncogenic role for WW domain-containing protein 1
(WWP1) has been suggested by genetic and functional analyses
in human cancers. Gene amplification has been detected in ap-
proximately 40% of prostate and breast primary tumors (Chen
et al., 2007a, 2007b). The expression of WWP1 has been found
to be frequently upregulated at the mRNA and protein level in
both tumor types. Knockdown of WWP1 induces growth arrest
and apoptosis in breast epithelial cancer cell lines, substantiat-
ing the concept that WWP1 promotes cell proliferation and sur-
vival of tumor cells (Chen et al., 2007b).
A recent report has revealed that p53 acts as a substrate for
WWP1 (Laine and Ronai, 2007). Binding of WWP1 to the p53
DNA-binding domain results in p53 ubiquitylation. The associa-
tion is not mediated through canonical WW-PY interactions,
though it is reinforced by the presence of the p53 PY motif. In
contrast to Huwe1, WWP1-mediated ubiquitylation of p53 pro-
motes its nuclear export and accumulation in the cytoplasm,
which results in diminished p53 transcriptional activity (Figure 2).
An interesting feedback loop has been proposed according to
which p53 represses WWP1 transcription (Laine and Ronai,
2007). Upon stress, inactivation of WWP1 would facilitate com-
plete p53 transcriptional induction. It is thus conceivable that
overexpression of WWP1 may contribute to breast and prostate
carcinogenesis by attenuating p53 transcriptional activation in14 Cancer Cell 14, July 2008 ª2008 Elsevier Inc.response to DNA-damaging insults. Though overexpression of
WWP1 has not been associated with known p53 status in breast
cancer cell lines, Chen and coworkers (2007b) have observed
that siRNA-induced downregulation of WWP1 does not signifi-
cantly reduce cell growth in breast cancer cell lines harboring
p53 mutations. These findings suggest that inhibition of WWP1
would sensitize only p53-proficient tumor cells to chemotherapy.
WWP1 has also been reported to target the Kru¨ppel-like fac-
tors KLF2 and KLF5 for ubiquitin-mediated proteolysis (Chen
et al., 2005b). KLFs are transcription factors that are thought to
suppress cell growth in cancer cells, thereby playing a critical
role in the progression of several tumors, including breast can-
cer. Of note, KLF5 is frequently downregulated in breast cancer
cell lines (Chen et al., 2002).
Although the closely related WWP1 and WWP2 E3s possess
binding specificity for the same PY motif-containing peptides
and share at least some common substrates (Martin-Serrano
et al., 2005), to date WWP2 has not been similarly implicated
in the ubiquitin-dependent regulation of tumor suppressor
molecules.
Itch
Itch was initially identified through genetic studies examining the
agouti locus on mouse chromosome 2 (Perry et al., 1998). The
18H mutation, which is associated with a darker coat color, re-
sults from a radiation-induced chromosomal inversion that dis-
rupts the expression of agouti and Itch genes (Perry et al., 1998).
There are an emerging number of Itch protein targets that have
been implicated in tumorigenesis and chemosensitivity (Table 2).
Two substrates implicated in human malignancies are the p53
homologs p73 and p63. Beyond their crucial involvement in de-
velopment and differentiation, both p73 and p63 share functional
similarities with p53, being able to mediate cell-cycle arrest and
apoptosis in response to DNA damage (Bergamaschi et al.,
2003; Irwin et al., 2003; Gressner et al., 2005). Although p73
and p63 genes are rarely mutated or inactivated in human can-
cers (Melino et al., 2002, 2003), they cooperate with p53 in tumor
Cancer Cell
ReviewFigure 3. A Model for PTEN Regulation by
Nedd4-1
Nedd4-1-mediated polyubiquitylation of PTEN
targets the phosphatase for proteasomal degra-
dation. Alternatively, monoubiquitylation of PTEN
leads to nuclear import and shuttling back to the
cytoplasm. Nuclear availability of ubiquitin-spe-
cific proteases would reverse the reaction and
allow nuclear accumulation of PTEN. The nuclear
PTEN pool can be then monoubiquitylated by
Nedd4-1 to be redirected to the cytoplasm. Be-
sides Nedd4-1 localization (cytoplasm versus
nucleus) and cellular levels (e.g., oncogenic over-
expression), the existence of a distinct set of
adaptors (indicated by ‘‘A’’ and ‘‘B’’) and/or post-
translational modifications (indicated by stars
and triangles) could select for the outcome of
PTEN modification by the E3. DUB, deubiquitylat-
ing enzymes.suppression and chemosensitivity (Flores et al., 2005). Like p53,
p73 and p63 expression is maintained at low levels in mamma-
lian cells, and their cellular activation is mainly controlled at the
posttranslational level. Both are polyubiquitylated in vivo and de-
graded via the proteasome (Bernassola et al., 2004; Rossi et al.,
2005, 2006). They display a unique C-terminal PY motif, absent
in p53, which renders them susceptible to Itch-mediated ubiqui-
tylation and degradation (Rossi et al., 2005, 2006).
Similarly to p53, p73 and p63 accumulate in tumor cell lines in
response to g irradiation or treatment with various chemothera-
peutic drugs (Bergamaschi et al., 2003; Irwin et al., 2003; Gress-
ner et al., 2005). Induction of p73 and p63 is at least partially
accomplished through Itch downregulation in response to DNA-
damaging agents (Rossi et al., 2005) (Figure 4). The molecular
mechanisms underlying the decline of Itch protein levels follow-
ing exposure of tumor cells to chemotherapy await further inves-
tigation.
Interestingly, loss or reduced expression of p73 and p63, pos-
sibly as result of altered proteasomal proteolysis, has been re-
ported in a number of human tumors, in which it correlated
with poor clinical outcome (Puig et al., 2003; Fang et al., 1999;
Urist et al., 2002). Thus far, no study has examined the potential
association between Itch dysregulation and protein expression
levels of p53 family members in human cancers. It is therefore
crucial to evaluate whether aberrant upregulation of Itch in tumor
cells, or enhanced enzymatic activity, may correlate with low
protein expression levels of p73 and p63 and posttranslational
suppression of the p53 family members, in a manner similar to
the HDM2:p53 paradigm.
On a similar note, the nonagouti 18H or Itchy mouse pheno-
type remains unclear with respect to tumorigenesis. On the
C57BL/6J background, Itch deficiency causes an autoim-
mune-like disease that is lethal at 6–8 months of age (Perry
et al., 1998). Although no systematic studies have been under-
taken to correlate Itch ablation with increased resistance to can-
cer development, possibly due to stabilization of the p53 family
members, differences in spontaneous tumor occurrence be-
tween normal and mutant mice have not yet been reported. Inthis respect, it must be remembered that the immune system
of the Itch mutant mice is seriously compromised and that their
life span is shortened by the severe inflammatory defects. Under
these circumstances, it might be difficult to reveal potentially
relevant differences in tumor latency as well as penetrance
between normal and mutant mice. It is likely that chemically in-
duced carcinogenesis or analysis of Itch deficiency on a different
background would clarify this important issue.
The Nedd4-binding partner-1 (N4BP1) protein, a molecular in-
teractor of Nedd4-1, is a negative regulator of Itch acting as
a competitor of its substrate recruitment ability (Oberst et al.,
2007). As a result, N4BP1 prevents Itch-mediated transfer of
ubiquitin to its protein targets, including p73 and p63, whose
transcriptional activity is enhanced by increased protein stabili-
zation (Figure 4). The competition mechanism implies that target
selection by Itch could be regulated either by changes in the re-
ciprocal affinity for the interactors (e.g., as a result of posttrans-
lational modifications) or by alterations of their cellular availabil-
ity. In this scenario, DNA-damage-induced accumulation of p73
or p63 could be achieved either through N4BP1 induction or via
chemical/conformational modifications of N4BP1, which in turn
would enhance its affinity for the E3 (Figure 4).
An intriguing Itch target crucially involved in controlling cell fate
specification and proliferation is the type I transmembrane re-
ceptor Notch1. Itch-mediated polyubiquitylation of the intracel-
lular domain (ICD) of membrane-tethered Notch1 results in the
degradation of the ICD following receptor activation, in turn an-
tagonizing Notch1 nuclear transcriptional activity (Qiu et al.,
2000; McGill and McGlade, 2003). In particular, Notch1 is unique
in the manner in which it associates with the HECT-type ligase.
The Notch1 ICD does not contain PY motifs but is presumed
to interact with Itch through its ankyrin repeats. A key role in
the negative regulation of Notch1-dependent signal transduction
is played by the adaptor protein Numb, which cooperatively en-
hances Itch-catalyzed ubiquitylation of the membrane-bound re-
ceptor. This effect is achieved through direct and simultaneous
binding of Numb to the Notch1 ICD and the WW1 and WW2 do-
mains of Itch (McGill and McGlade, 2003). By this means, NumbCancer Cell 14, July 2008 ª2008 Elsevier Inc. 15
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ReviewTable 2. Itch Substrates and Regulators
Substrate Biological Function Relationship with the Itchy Mouse Phenotype
c-Jun, JunB Th2 cell differentiation/anergy Th2-mediated allergy/autoimmune disease
JunB Th2 cell differentiation/anergy Th2-mediated allergic airway inflammation and
atopic dermatitis/autoimmune disease
PLC-g1/PKCq T cell anergy resistance to anergy induction/autoimmune
disease
Notch1 autoimmunity, cancer autoimmune disease/skin proliferation/
differentiation defects?
Smad2 TbR signaling, cancer autoimmune disease?
p73 apoptosis, neural development, cancer unknown
p63 apoptosis, epithelial development, cancer skin proliferation/differentiation defects?
c-FLIPL apoptosis unknown
ErbB4 epithelial kinase receptor, cancer unknown
CXCR4 agonist-dependent sorting of G protein-coupled
receptors
unknown
TRPV4, TRPC4 regulation of channel expression at the cell
membrane
unknown
Regulator Effect on Itch Catalytic Activity or Substrate
Recognition Ability
Mechanism of Regulation
JNK positive phosphorylation (Ser/Thr kinase)
Fyn negative phosphorylation (Tyr kinase)
USP9X/FAM positive deubiquitylation
Itch positive/negative? ubiquitylation
N4BP1 negative binding (adaptor)
Numb positive binding (adaptor)
Ndfip1 positive binding (adaptor)
PLC-g1, phospholipase C-g1; PKCq, protein kinase q; c-FLIPL, cellular FLICE-inhibitory protein; CXCR4, chemokine receptor 4; Ndfip1, Nedd4 family
interacting protein-1.may act as an adaptor facilitating or stabilizing the WW domain/
ankyrin repeat-mediated interaction between Itch and its sub-
strates.
Notch1 exerts opposite functions in tumor development, be-
ing able to act as either an oncogene or a tumor suppressor de-
pending on signal strength, timing, and cell context (Maillard and
Pear, 2003). The Notch1 tumor suppressor function seems to be
restricted to tissues in which Notch1 signaling orchestrates the
spatiotemporal progression of terminal differentiation such as
epithelia, including the epidermis. In mouse keratinocytes,
Notch1 promotes exit from the cell cycle and entry into the differ-
entiation program by committing basal progenitors to a spinous
cell fate. Conditional ablation of Notch1 in murine epidermis re-
sults in skin carcinoma development and increased chemically
triggered skin carcinogenesis (Nicolas et al., 2003).
Although a direct correlation with cancer biology has not yet
been explored, biochemical and genetic studies have shown
that a crucial regulatory mechanism of Itch catalytic activation
is its Jun N-terminal kinase 1 (JNK1)-mediated Ser/Thr phos-
phorylation (Gao et al., 2004). In its unphosphorylated state,
Itch enzymatic activity is negatively regulated through intramo-
lecular interactions between the central region, including the
WW motifs, and the C-terminal HECT domain (‘‘closed’’ con-
formation). Following phosphorylation, Itch undergoes a con-
formational change (‘‘open’’ conformation) that destabilizes
the self-inhibitory intramolecular interactions, thus allowing16 Cancer Cell 14, July 2008 ª2008 Elsevier Inc.substrate recruitment and catalytic activation (Gallagher et al.,
2006).
Smurfs
Smad ubiquitylation regulatory factor 1 (Smurf1) and Smurf2 an-
tagonize the transforming growth factor-b (TGF-b) pathway
through ubiquitin-mediated degradation of crucial components
of its signaling transduction machinery. One of the molecular
mechanisms to prevent continuous TGF-b signaling in the ab-
sence of ligand stimulation is the Smurf-mediated elimination
of phosphorylated TGF-b receptor (TbR)-regulated Smad (R-
Smad) proteins by the proteasome (Zhang et al., 2001). The over-
all basal levels of R-Smads are also regulated by Smurfs (Zhu
et al., 1999). This is achieved in order to prevent spurious activa-
tion of the TGF-b cascade and to adjust the intensity of respon-
siveness of a particular cell to TGF-b signaling. With the excep-
tion of Smad4 and Smad8, all of the Smads possess a PY motif.
Smurf1 specifically targets Smad1 and Smad5, whereas Smurf2
displays a broader specificity toward the family members (see
Table 1).
A unique property of the Smads is their ability to function as
adaptor molecules for the Smurfs or other members of the
HECT family. This mode of action is exemplified by the inhibitory
Smad (I-Smad) Smad7, which, acting in concert with Smurf1 and
Smurf2, assists the HECT E3s in recruiting the PY-deficient TbR-I
(Kavsak et al., 2000). In addition, the auxiliary role of Smad7 is
accomplished by presenting the E2 to Smurf2 and enforcing their
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ReviewFigure 4. Itch-Mediated Regulation of p73-Induced Apoptosis
In unstressed cancer cells, the steady-state levels of p73 are kept low by the ubiquitylating activity of Itch. p73 upregulation in response to treatment of tumor cells
with DNA-damaging agents may arise from (1) Itch downregulation and/or (2) the inhibitory competitive action exerted by N4BP1 on Itch substrate recruitment
ability. p73 accumulation leads to increased transactivation of proapoptotic target genes.interaction (Ogunjimi et al., 2005). This is mediated by the N-ter-
minal domain of Smad7, which binds to both the HECT domain
and, via a leucine-rich motif, UbcH7, resulting in enhanced
Smurf2 catalytic activity. In addition, Smurf1 recruits activin
and BMP receptors through its association with I-Smads.
Smad6 and Smad7 also act as a bridge to target non-Smurf
HECT E3s, such as Nedd4-2 and WWP1 (see Table 1), to the
TbR complexes. Smad7 serves as a protein adaptor for both
Smurfs to direct Smad4 for proteasomal destruction (Moren
et al., 2005). The Smurf/I-Smad-mediated proteasomal and lyso-
somal degradation of TGF-b-like receptors and co-Smad con-
tributes to the attenuation or termination of the family signaling
events.
A distinct role as an auxiliary molecule is played by Smad2,
which upon receptor stimulation and phosphorylation forms
a complex with Smurf2 through WW-PY domain-mediated inter-
actions. As a result, Smurf2 is recruited to the transcriptional co-
repressor SnoN, which in turn is targeted for ubiquitin-mediated
proteolysis (Bonni et al., 2001). These findings define temporally
distinct roles for Smurf2 in regulating the TGF-b pathway, being
the activation or attenuation of TGF-b signaling depending on the
association of Smurf with different Smad proteins.
Somatic and germline mutations in cancer cells are present at
different levels of the TGF-b signaling pathway, including genes
encoding TbR-I, TbR-II, Smad4, and Smad2 (Markowitz et al.,
1995; Maurice et al., 2001). Insensitivity to TGF-b results in un-
controlled cell proliferation and contributes to tumorigenesis.
As they are essential modulators of the TGF-b cascade, it is
not surprising that dysregulation or dysfunction of Smurfs ham-
pers TGF-b signaling. Aberrant downregulation of TGF-b signal-
ing allows tumor cells to escape TGF-b-induced growth inhibi-
tion and thus promotes cancer development. Genetic
amplification of Smurf1 and overexpression of Smurf2 are asso-
ciated with pancreatic and esophageal squamous cell carcino-
mas, respectively (Fukuchi et al., 2002). Increased Smurf2 pro-
tein expression correlates with higher invasiveness and
metastatic potential and poorer prognosis. Interestingly, several
Smad2 and Smad4 oncogenic inactivating mutations known to
interfere with their transcriptional function in cancer cells alsoaffect their protein stability through accelerated degradation
(Xu and Attisano, 2000; Maurice et al., 2001). In addition, abnor-
mal expression of the adaptor protein Smad7 has been observed
in a subset of human cancers, including follicular thyroid carci-
noma cell lines and endometrial cancers (Cerutti et al., 2003;
Dowdy et al., 2005). Smad7 overexpression may represent a fur-
ther mechanism for the abrogation of the TGF-b response in tu-
mor cells.
While the cytostatic actions of TGF-b are a barrier to tumor
emergence, during cancer progression tumor cells can acquire
the ability to overproduce TGF-b, which in turn starts to behave
as an autocrine tumor-promoting factor by enhancing invasion
and metastasis. In later stages of the disease, Smurf2 activity
is inhibited through interaction with the adaptor protein RNF11,
which is highly expressed in invasive breast cancers (Subrama-
niam et al., 2003). RNF11 is though to promote Smurf2 protein
ubiquitylation and proteasomal degradation, thereby enhancing
TGF-b signaling and its tumor-promoting activity.
HECT E3s as Potential Cancer Targets
The hierarchical nature of the ubiquitin-proteasome system pro-
vides a rich source of molecular targets for anticancer therapies.
The clinical relevance of targeting the ubiquitin-proteasome sys-
tem has been revealed by the use of bortezomib (Millennium
Pharmaceuticals, Inc.’s Velcade, also previously known as
PS-341), a highly selective and reversible inhibitor of the chymo-
trypsin-like activity of the proteasome. Bortezomib has been
evaluated in a number of preclinical and clinical trials for solid
and hematological malignancies (reviewed in Voorhees and
Orlowski, 2006). It is presently approved by the US Food and
Drug Administration for treatment of relapsed and refractory
multiple myeloma, for which manageable side effects have been
reported. Unfortunately, the clinical activity of bortezomib in
other forms of hematological malignancies as well as solid tu-
mors has so far been less promising, with partial or no response.
Given the lack of specificity of proteasome inhibitors, manipu-
lating less universal features of the ubiquitin-proteasome sys-
tem, such as the E2s or the neddylation system (which targets
certain RING-finger E3s), may in principle be a useful therapeuticCancer Cell 14, July 2008 ª2008 Elsevier Inc. 17
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cific substrate recognition properties of E3s indicate ubiquitin li-
gases as even more specific and effective therapeutic targets.
Targeting individual E3s would selectively stabilize a particular
or limited number of protein substrates, thus possibly limiting un-
toward side effects. Hence, drugs targeting E3s promise a better
therapeutic ratio than proteasome inhibitors. Importantly, E3s
show a clear involvement in oncogenesis, as indicated in this
review. As one example, downregulation of Itch, with its cancer-
related substrates (Table 2), is able to sensitize cells to chemo-
therapy (Hansen et al., 2007).
However, the advantage of targeting E3s is partially reduced
by (1) the promiscuity of enzymes and substrates (each E3 usu-
ally degrades more than one substrate, and each substrate can
be degraded by several E3s), (2) the unknown nature of the ‘‘cru-
cial’’ oncogenic substrate or substrates for each individual E3,
and (3) the intrinsic technical difficulties inherent in high-through-
put screenings to identify small-molecule inhibitors of E3s.
Blocking E3 functions could be achieved by chemically inhibiting
E2 recruitment or, alternatively, by preventing specific substrate
recognition by E3s (either directly or allosterically).
In this regard, the HECT family, with its intrinsic catalytic activ-
ity, may be easier to inhibit than E3s belonging to the RING-finger
family. This is because, in contrast to the RING-finger E3s, HECT
E3s have intrinsic enzymatic ubiquitin transfer activity via a
mechanism somehow reminiscent of E2s. In fact, HECT E3s, fol-
lowing binding of a ubiquitin-charged E2, form a thioester bond
between their own active-site Cys and the ubiquitin C terminus.
Subsequently, the HECT domain catalyzes the formation of an
isopeptide bond between the 3-N side chain of a Lys residue
and the ubiquitin C-terminal carboxylate. Catalysis requires a
rotation of the N and C lobes of the HECT domain on a specific
polypeptide hinge linking region (Verdecia et al., 2003; Diao
et al., 2008).
So far, most high-throughput screenings have been performed
with both E3 and substrate, or using the ability of some E3s to
self-ubiquitylate. In this latter case, although the E3:substrate
recognition inhibitors are missing, there is a stronger chance to
inhibit the active catalytic site.
The identification of specific HDM2 inhibitors has been re-
ported with success by several groups (e.g., Yang et al., 2005),
showing that inhibitors of E3s are already a reality. Even though
this indicates a proof of principle of the feasibility of this difficult
road, this is not by any means the end of the story.
Concluding Remarks
Ubiquitin-dependent proteolytic and nonproteolytic pathways
play pivotal roles in cancer cell proliferation and apoptosis. The
data reviewed here illustrate how certain HECT-type E3s may
contribute to tumorigenesis by controlling the ubiquitylation of
tumor suppressors and oncoproteins. Inappropriate degrada-
tion of these substrates due to aberrant expression, dysfunction,
or altered regulation of the HECT E3s would be tightly linked to
malignant transformation and chemoresistance. In view of their
substrate specificity, the E3s represent attractive targets for can-
cer therapy. In this scenario, therapeutic strategies that inhibit
oncogenic HECT E3s should restore normal expression of tumor
suppressors and ultimately induce regression of malignant le-
sions. A better understanding of the oncogenic potential of the18 Cancer Cell 14, July 2008 ª2008 Elsevier Inc.HECT-type E3s will likely lead to the identification and develop-
ment of biomarkers and drug targets for cancer treatment.
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